Nanjing Immunophage Biotech
Nanjing Immunophage Biotech is a Chinese developer in Nanjing that sponsors 2 registered cancer trials of IPG1094 and IPG7236.
Overview
Nanjing Immunophage Biotech appears on ClinicalTrials.gov as the industry sponsor of 2 interventional cancer trials (phase 1/2), testing IPG1094, IPG7236, Toripalimab in solid tumor, advanced solid tumor. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.
Similar pages
not linked directly; found by shared links- TreatmentIPG1094
Shares Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients and the tag registry-only.
- CompanyBeijing Gene Key Life Technology
Shares the tags china, registry-only.
- CompanyBeijing Konruns Pharmaceutical
Shares the tags china, registry-only.
- CompanyBeijing Mabworks Biotech
Shares the tags china, registry-only.
- CompanyBeijing Pearl Biotechnology Limited Liability Company
Shares the tags china, registry-only.
- CompanyBeijing Scitech-Mq Pharmaceuticals
Shares the tags china, registry-only.
- CompanyBeijing Tide Pharmaceutical
Shares the tags china, registry-only.
- CompanyBinhui Biopharmaceutical
Shares the tags china, registry-only.